RxDoctor Payments Data

Amer Abdulla, MD

Cardiovascular Disease · Galveston, TXNPI 1437533205

Payments from drug & device makers

$323,958in general payments, 2019–2025

Across 57 payments — averaging $5683.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$305K
  • Bracco Diagnostics Inc.$17K
  • Boston Scientific$336
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$318
  • Astellas Pharma US Inc$223
  • Amgen$177
  • plus $994 from 13 others

What the payments were for

  • Food & beverage$1,8501%
  • Education$1990%
  • Other$304,69399%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$323,958 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$82,505
Medicare patients
1,109
Services billed
2,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$105,592
XareltoRivaroxaban11$18,265
JardianceEmpagliflozin13$14,445
EntrestoSacubitril/Valsartan11$12,278
Atorvastatin Calcium149$1,676
Clonidine13$1,330
Ezetimibe79$1,315
Rosuvastatin Calcium74$1,201
Metoprolol Succinate66$1,132
Losartan Potassium78$676
ClopidogrelClopidogrel Bisulfate33$519
Hydralazine Hcl28$478
Carvedilol67$419
Amlodipine Besylate70$398
Lisinopril38$345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$105,592112 claims
Johnson & JohnsonXarelto$33$18,26511 claims
NovartisEntresto$118$12,27811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →